P1966Impact of coronary artery calcification on long-term outcomes after implantation of first and second-generation drug-eluting stents: a patient-level analysis of 18 randomized trials — Paul Guedeney (2019) | RDL Network
P1966Impact of coronary artery calcification on long-term outcomes after implantation of first and second-generation drug-eluting stents: a patient-level analysis of 18 randomized trials
European Heart Journal 40(Supplement_1)
Article 2019 English
Authors
PG
Paul Guedeney
BC
Bimmer E. Claessen
RM
Roxana Mehran
Abstract
1 min read
Background Available data on the long-term impact of coronary artery calcification (CAC) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are limited. Purpose We evaluated the long-term impact of CAC on outcomes after PCI and the respective performance of first- and second-generation DES. Methods We pooled patient-level data from 18 randomized trials evaluating DES categorized according to the presence of angiographic core lab-confirmed moderate or severe CAC in any target lesion. Outcome measures of interest were the patient-oriented composite endpoint (POCE; death, myocardial infarction [MI], or any revascularization), the device-oriented composite endpoint of target lesion failure (TLF; cardiac death, target vessel MI or ischemia-driven target lesion revascularization), and definite or probable stent thrombosis (ST). Multivariable Cox proportional regression with study as a random effect was used to assess 5-year outcomes. Results A total of 19,833 patients were included. Moderate or severe CAC was present in 6211 (31.3%) patients and associated with increased 5-year risk of the POCE (adjHR 1.12, 95% CI 1.05–1.20, p<0.001), TLF (adjHR 1.21, 95% CI 1.09–1.35, p<0.001), and a trend for greater ST (adjHR 1.24, 95% CI 0.99–1.54, p=0.06). In patients with CAC, second-generation DES were associated with a reduction in the 5-year risk of TLF and ST, and a trend for reduced POCE compared with first-generation DES (Table). Conclusion In this large-scale study, target lesion moderate or severe CAC was associated with adverse patient- and device-related outcomes at 5 years, risks that were reduced but not eliminated with second-generation DES. Acknowledgement/Funding This investigator-sponsored study was funded by Abbott Vascular.
Paul Guedeney, Bimmer E. Claessen, Roxana Mehran, Gary S. Mintz, Mengdan Liu, Sabato Sorrentino, Gennaro Giustino, Serdar Farhan, Martin B. Leon, Patrick W. Serruys, Pieter C. Smits, Clemens von Birgelen, Ziad A. Ali, Philippe Généreux, Björn Redfors, Mahesh V. Madhavan, Ori Ben‐Yehuda, Gregg W. Stone
Gennaro Giustino, Ioannis Mastoris, Usman Baber, Samantha Sartori, Gregg W. Stone, Martin B. Leon, Patrick W. Serruys, Adnan Kastrati, Stephan Windecker, Marco Valgimigli, George Dangas, Clemens von Birgelen, Pieter C. Smits, David E. Kandzari, Søren Galatius, William Wijns, Philippe Gabríel Steg, Giulio Stefanini, Melissa Aquino, Marie-Claude Morice, Edoardo Camenzind, Giora Weisz,
Gennaro Giustino, Rafael Harari, Usman Baber, Samantha Sartori, Gregg W. Stone, Martin B. Leon, Stephan Windecker, Patrick W. Serruys, Adnan Kastrati, Clemens von Birgelen, Takeshi Kimura, Giulio Stefanini, George Dangas, William Wijns, Philippe Gabríel Steg, Marie‐Claude Morice, Edoardo Camenzind, Giora Weisz, Pieter C. Smits, Sabato Sorrentino, Madhav Sharma, Serdar Farhan, Michela Faggioni,
Discussion(0)
No comments yet. Be the first to comment.